Leqembi’s Initial Pricing Won’t Factor in Benefits in Long-Term Care

Chuikyo Joint Meeting of Drug Pricing & CEA Subcommittees on Oct. 18 A key Japanese reimbursement policy panel on October 18 agreed to set the list price of the Alzheimer’s therapy Leqembi (lecanemab) in accordance with the existing rules, effectively...read more